You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for ACPT-I
ACPT-I is a agonist for group III mGlu receptors (EC50 values are 7.2 and 8.2 μM for mGlu4a and mGlu8 respectively). Anticonvulsant in mice.
Sold with the permission of the CNRS
Technical Data for ACPT-I
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for ACPT-I
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for ACPT-I
The following data is based on the product molecular weight 217.18. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||9.21 mL||46.04 mL||92.09 mL|
|2.5 mM||1.84 mL||9.21 mL||18.42 mL|
|5 mM||0.92 mL||4.6 mL||9.21 mL|
|25 mM||0.18 mL||0.92 mL||1.84 mL|
References for ACPT-I
References are publications that support the biological activity of the product.
Acher et al (1997) Synthesis and pharmacological characterization of aminocyclopentanetricarboxylic acids: new tools to discriminate between metabotropic glutamate receptor subtypes. J.Med.Chem. 40 3119 PMID: 9301676
Chapman et al (2001) Anticonvulsant activity of a mGlu4α receptor selective agonist, (1S,3R,4S)-1-aminocyclopentane-1,2,4-tricarboxylic acid. Eur.J.Pharmacol. 424 107 PMID: 11476756
De Colle et al (2000) Pharmacological characterization of the rat metabotropic glutamate receptor 8a revealed strong similarities and slight differences with the type 4a receptor. Eur.J.Pharmacol. 394 17 PMID: 10771029
If you know of a relevant reference for ACPT-I, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: ACPT-I, ACPT-I supplier, Group, III, agonists, Receptors, mGlu4, mGlu6, mGlu7, mGlu8, mGluR4, mGluR6, mGluR7, mGluR8, Glutamate, Metabotropic, (Metabotropic), 1111, Tocris Bioscience
1 Citation for ACPT-I
Citations are publications that use Tocris products. Selected citations for ACPT-I include:
Domin et al (2014) Group III mGlu receptor agonist, ACPT-I, exerts potential neuroprotective effects in vitro and in vivo. Proc Natl Acad Sci U S A 26 99 PMID: 24402869
Do you know of a great paper that uses ACPT-I from Tocris? Please let us know.
Reviews for ACPT-I
There are currently no reviews for this product. Be the first to review ACPT-I and earn rewards!
Have you used ACPT-I?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.